SYRE
Spyre Therapeutics, Inc.
$102.91−3.91 (−3.66%)Close Nov 12, 2026
Apr 7, 2016 – Nov 12, 2026, Dividends reinvested
- Final balance
- $4,213
- CAGR
- −7.83%
- Max drawdown
- −99.12%
- Sharpe ratio
- 0.36
Loading the growth chart…
Growth of $10,000
Trailing returns (%)
SYRE's average annual return was −3.58% over the last 10 years, through Nov 12, 2026. $10,000 in SYRE on Nov 11, 2016 fell to $6,942 by Nov 12, 2026, with dividends reinvested.
Total
- 1M
- +19.80%
- 3M
- −1.13%
- 6M
- +37.14%
- YTD
- +214.13%
- 1Y
- +339.22%
Per year
- 3Y
- +121.34%
- 5Y
- −10.18%
- 10Y
- −3.58%
- Since 2016
- −7.83%
Annual returns
2016 from Apr 7 · 2026 through Nov 12
SYRE returns by year
| Year | Return |
|---|---|
| 2026 through Nov 12 | +214.13% |
| 2025 | +40.72% |
| 2024 | +8.18% |
| 2023 | +91.29% |
| 2022 | −90.53% |
| 2021 | −39.64% |
| 2020 | +3.01% |
| 2019 | +2.00% |
| 2018 | +38.45% |
| 2017 | +24.37% |
| 2016 from Apr 7 | −55.48% |
Metrics
Since 2016| Volatility | 133.88% |
|---|---|
| Sortino ratio | 0.83 |
| Calmar ratio | −0.08 |
| Best year, 2023 | +91.29% |
| Worst year, 2022 | −90.53% |
| Positive years | 7 of 9 |
| Longest drawdown | 10.6 years |
Worst drawdowns
Since 2016| Decline | Peak | Bottom | Recovered | Length |
|---|---|---|---|---|
| −99.1% | Apr 2016 | Jun 2023 | Not yet | 10.6 years so far |